Rapid eradication of a bulky melanoma mass with one dose of immunotherapy

New England Journal of Medicine

Volumn 372, Issue 21, 2015, Pages 2073-2074

  Chapman, Paul B ^a   D'Angelo, Sandra P ^a   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; BRAF GENE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ERADICATION; FEMALE; GENE MUTATION; HUMAN; IMMUNOTHERAPY; LETTER; LYMPHADENOPATHY; METASTATIC MELANOMA; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; SUBCUTANEOUS NODULE; MELANOMA; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOTHERAPY; MELANOMA; MIDDLE AGED;

EID: 84929773754     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1501894     Document Type: Letter

References (3)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23. [Erratum, N Engl J Med 2010;363:1290.]
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
3. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.